Clinical Trials Directory

Trials / Completed

CompletedNCT04294433

Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children

Clinical Trial to Assess Immunogenicity of 2 Versus 3 Doses of Hepatitis B Vaccines When Administered to Children Aged 2 to 18 Months

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
431 (actual)
Sponsor
Laval University · Academic / Other
Sex
All
Age
2 Months – 19 Months
Healthy volunteers
Accepted

Summary

The main objective of this study is to compare the immunogenicity of the hepatitis B component in children vaccinated with (I) two doses of Infanrix-hexa administered at 2 and 12 months of age versus (II) one dose of Infanrix-hexa and one dose of Twinrix administered respectively at 2 and 12 months of age versus (III) three doses of Infanrix-hexa administered at 2, 4 and 18 months of age (comparator).

Detailed description

In the province of Quebec, Canada, hepatitis B vaccination of infants involves three doses of vaccine, 2, 4 and 18 months of age. However, in the current epidemiological context (virtual absence of new cases in young Quebecers) and taking into account scientific data which consistently show a high immunogenicity and efficacy of two doses of hepatitis B vaccine, the relevance of the second dose given at the age of 4 months is questionable. this study is designed to compare the immunogenicity of the hepatitis B component in children vaccinated with (I) two doses of Infanrix-hexa administered at 2 and 12 months of age versus (II) one dose of Infanrix-hexa and one dose of Twinrix administered respectively at 2 and 12 months of age versus (III) three doses of Infanrix-hexa administered at 2, 4 and 18 months of age (comparator).

Conditions

Interventions

TypeNameDescription
BIOLOGICALInfanrix-hexaVaccines administrated according to product monographs' recommendations
BIOLOGICALInfanrix-hexa and Twinrix JuniorVaccines administrated according to product monographs' recommendations

Timeline

Start date
2018-06-11
Primary completion
2023-12-30
Completion
2023-12-30
First posted
2020-03-04
Last updated
2026-01-20

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT04294433. Inclusion in this directory is not an endorsement.